Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Jan 17, 2025 1:30pm
96 Views
Post# 36409257

Moving On

Moving OnIt is official The assets of Replicel are now in control of the new company formed by Andrew Schutte.

A little confusion as to who owns this new company (1456390 B.C. Ltd.)

The N/R yesterday posted after the meeting stated the following:


"Shareholders approved the proposed asset sale and royalty transaction with 1456390 B.C. Ltd., a company wholly owned by Andrew Schutte, the company's president and chief executive officer."

In the Information Circular that was sent out by your brokerage house for the AGM meeting yesterday states on page 46:
"It is expected that Messrrs. Austring, Kwok, Boddington and McElwee will together, hold approximately 22% of the equity of the acquiror, with the remainder of the equity interest in the Acquiror being held by Mr. Schutte".

Which is it ?



<< Previous
Bullboard Posts
Next >>